Jeffrey Schwartz is a Managing Director of Bain Capital Life Sciences, where he is a founding member of the team. Prior to co-founding Bain Capital Life Sciences in 2016, he was a leader within the healthcare vertical of Bain Capital Private Equity. He currently is a board member of Hugel, QuVa Pharma, and Springworks Therapeutics. Since joining Bain Capital, Mr. Schwartz has been actively involved in a wide spectrum of healthcare companies in which Bain Capital Private Equity has made investments
Prior to joining Bain Capital, Mr. Schwartz served as an Equity Research Analyst at Lehman Brothers, working in both New York and London.
Mr. Schwartz received an MBA from The Wharton School at the University of Pennsylvania, where he was a Palmer Scholar. He graduated magna cum laude from Yale University with a BA in economics.
Rob has more than 20 years of leadership experience. Before joining Rapid Micro Biosystems, he was Vice President and General Manager, Americas, for the Microbiology Division of Thermo Fisher Scientific.
Previously, Rob was the VP of Global Strategy, Marketing, and Business Development for Fisher Scientific. He’s also held senior positions at McKesson Corporation and its affiliates, including EVP Operations and Development and National Vice President of Sales and Business Development.
Earlier in his career, Rob was a senior consultant within the Life Sciences and Healthcare practice of Deloitte Consulting and an aviation officer with the U.S. Army.
Rob holds a BS in Economics from the United States Military Academy at West Point and an MBA from Columbia University, where he was the Dr. Donald Bibeault Scholar
Mr. Cashman is a co-founder of Protez Pharmaceuticals Inc. and most recently served as Director, President, and CEO. Protez was acquired by Novartis in 2008.
He has 30 years of experience in the pharmaceutical industry including prior roles as President and CEO, Message Pharmaceuticals, and as Vice President, Sales and Marketing, for both Pfizer and SmithKline Beecham.
Mr. Cashman also serves on the board of directors of the Science Center, Noble Biomaterials, Marinus Pharmaceuticals, and MBF Therapeutics.
David Hirsch is a founder and Managing Director of Longitude Capital. He focuses on investments in biotechnology. From 2005 to 2006, Dr. Hirsch was a Vice President of Pequot Ventures where he worked in the life sciences practice.
Prior to Pequot, Dr. Hirsch was an Engagement Manager in the pharmaceutical practice of McKinsey & Company. While at McKinsey, he worked with many large pharmaceutical companies across a range of projects including clinical and commercial strategies, M&A evaluations, portfolio prioritization, and managed care strategy.
Dr. Hirsch currently serves on the boards of Civitas Therapeutics and Precision Therapeutics and is a board observer at InfaCare Pharmaceuticals and Xanodyne Pharmaceuticals. He is also actively involved with Longitudes's investments in Amarin (NASDAQ: AMRN) and Corcept Therapeutics (NASDAQ: CORT), as well as prior investments in Horizon Therapeutics and Sequenom (NASDAQ: SQNM).
Dr. Hirsch holds a Ph.D. in Biology from Massachusetts Institute of Technology, and MD from Harvard Medical School, and a BA in Biology from The Johns Hopkins University.
Richard has more than 25 years of financial and operational experience in the healthcare industry. Most recently, as Managing Partner of Quaker Partners, a healthcare-focused venture capital and growth equity firm with $700 million under management, he led investments and served as an active Chairman or board member of more than a dozen private and publicly traded companies, including Rapid Micro Biosystems.
Previously, he held positions in sales, marketing, global business development, and venture capital at GlaxoSmithKline (GSK) and its corporate venture arm, S.R. One.
Richard began his career as a Certified Public Accountant initially with KPMG, and subsequently with Rudolph, Palitz (now RSM). Richard’s practice had a significant emphasis on the healthcare and emerging businesses sectors.
Richard is an adjunct faculty member at Lehigh University and a Director of Strongbridge Biopharma (NASDAQ: SBBP). He holds a BA in Business Administration and Accounting from Franklin and Marshall College and an MBA with honors in Health Administration and Policy from the University of Chicago.
Mr. Ricciardi spent his entire 39-year career at Pfizer Inc., retiring in 2011. At retirement, Nat held the positions of President, Pfizer Global Manufacturing and Senior Vice President, Pfizer Inc.
In addition to his corporate leadership role, Nat was directly responsible for all of Pfizer’s internal and external supply organization, a global enterprise with as many as 38,000 employees and more than 100 manufacturing facilities supplying small and large molecule pharmaceuticals, vaccines, consumer, nutrition and animal health products.
He played a leadership role in shaping a mission-driven and values-based culture as the company went through phases of growth, mergers, and acquisitions and transformation. His relentless focus on Quality and Compliance became a competitive advantage.
Mr. Ricciardi earned a degree in Chemical Engineering from the City College of New York (CCNY) and an MBA in Finance and International Business from Fordham University. He serves on the Board of Directors of Dynavax Technologies, Inc., Asterias Biotherapeutics, Inc., and is on the Strategic Advisory Board of HealthCare Royalty Partners. He is currently a member of the Board of the 21st Century Foundation of CCNY.